4//SEC Filing
Sullivan Christopher Ryan 4
Accession 0001578563-25-000198
CIK 0001534120other
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 4:11 PM ET
Size
8.7 KB
Accession
0001578563-25-000198
Insider Transaction Report
Form 4
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-28+24,200→ 24,206 total - Tax Payment
Common Stock
2025-03-28$8.46/sh−7,285$61,631→ 16,921 total - Exercise/Conversion
Restricted Stock Units
2025-03-28−24,200→ 48,400 total→ Common Stock (24,200 underlying)
Footnotes (2)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.
Documents
Issuer
Avalo Therapeutics, Inc.
CIK 0001534120
Entity typeother
Related Parties
1- filerCIK 0001810417
Filing Metadata
- Form type
- 4
- Filed
- Mar 31, 8:00 PM ET
- Accepted
- Apr 1, 4:11 PM ET
- Size
- 8.7 KB